SEC Form 4 · accession 0001760123-26-000004
DiaMedica Therapeutics Inc. · DMAC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dietrich John Pauls
Officer — President & CEO · Director
Period of report
Aug 10, 2026
Accepted (ET)
Aug 12, 2026 · 4:23 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001401040
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Voting Common Shares, no par value per shareF1,F2 | Aug 10, 2026 | A | 60,200 | $0.00 | A | 128,791 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The restricted stock units will vest in four equal installments, each on the first, second, third, and fourth anniversaries of the grant date, provided, however, that the participant remains continuously employed by or provides services to the Company, or one of its Subsidiaries or Affiliates, through the applicable vesting date.
- F2Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan.